Ann: Positive Results for Australian Prospective Paediatric Study, page-79

Worth re-posting from last week for the many new investors that will come to this forum now that positive Australian results are out and ResAppDx algorithms have been validated.

Good Aus pedi results = TGA + CE approvals

It might also mean CFDA approvals!!

"China is planning to accept data generated from clinical trials run overseas. The proposal is part of a suite of changes put forward by the State Council to boost China’s support for innovative drugs and devices and accelerate their path to patients."

See this link:
https://www.raps.org/news-articles/...ial-data-for-accelerated-approvals-(10-octobe

This would be MASSIVE. The telehealth numbers in China are staggering.

In 2017 PingAn had 370,000 telehealth consults per day and was growing at +100% per year (this is not a typo).

We are told that 30-50% of all consults are for respiratory disease. That's around 100k - 200k consults for respiratory disease per day and at only $5/test this is USD 500k - 1m revenue per day!

The opportunity in the China market is huge.  The potential revenue numbers are staggering.

There is no other product on the market like ResAppDx.

Currently a steal at 0.26 IMO.